12. Ulcerative Colitis

  1. John WD McDonald Professor of Medicine3,
  2. Andrew K Burroughs Professor of Hepatology Consultant Physician/Hepatologist4,
  3. Brian G Feagan Professor of Medicine3 and
  4. M Brian Fennerty Professor of Medicine5
  1. Derek P Jewell1,
  2. Lloyd R Sutherland2,
  3. John WD McDonald Professor of Medicine3 and
  4. Brian G Feagan Professor of Medicine3

Published Online: 22 JUL 2010

DOI: 10.1002/9781444314403.ch12

Evidence-Based Gastroenterology and Hepatology, Third Edition

Evidence-Based Gastroenterology and Hepatology, Third Edition

How to Cite

Jewell, D. P., Sutherland, L. R., McDonald, J. W. and Feagan, B. G. (2010) Ulcerative Colitis, in Evidence-Based Gastroenterology and Hepatology, Third Edition (eds J. W. McDonald, A. K. Burroughs, B. G. Feagan and M. B. Fennerty), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444314403.ch12

Editor Information

  1. 3

    Robarts Clinical Trials, Robarts Research Unit, University of Western Ontario, London, Ontario, Canada

  2. 4

    The Royal Free Sheila Sherlock Liver Centre, Royal Free Hospital, and University College London, London, UK

  3. 5

    Oregon Health and Science University, Division of Gastroenterology and Hepatology, Portland, Oregon, USA

Author Information

  1. 1

    Experimental Medicine Division, John Radcliffe Hospital, Oxford, UK

  2. 2

    Department of Community Health Sciences, University of Calgary, Health Sciences Centre, Calgary, Canada

  3. 3

    Robarts Clinical Trials, Robarts Research Unit, University of Western Ontario, London, Ontario, Canada

Publication History

  1. Published Online: 22 JUL 2010
  2. Published Print: 10 SEP 2010

ISBN Information

Print ISBN: 9781405181938

Online ISBN: 9781444314403

SEARCH

Keywords:

  • inflammatory bowel disease (IBD);
  • Inflammatory Bowel Diseases and the Inflammatory Bowel South Eastern Norway (IBSEN);
  • dysplasia-associated lesions or masses (DALMs);
  • Azathioprine and 6-mercaptopurine;
  • Anti-integrin monoclonal antibodies;
  • Anti-interleukin-2 receptor antibodies;
  • Anti-tumor necrosis factor (TNF) monoclonal antibodies;
  • epidermal growth factor (EGF);
  • Algorithm for management of ulcerative colitis

Summary

This chapter contains sections titled:

  • Introduction

  • Histological diagnosis

  • Prognosis

  • Cancer surveillance (see also Chapter 17)

  • Treatment

  • References